Literature DB >> 19996642

Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.

Manfred Stoehrer1, Andreas Wolff, Guus Kramer, Rainer Steiner, Dieter Lmöchner-Ernst, Dirk Leuth, Ute Steude, Herbert Ruebben.   

Abstract

INTRODUCTION: This retrospective study describes the results of botulinum toxin A detrusor injections following a fixed protocol in 216 patients with untreatable neurogenic detrusor overactivity and incontinence. A comparison is made between the two preparations currently available, and the efficacy of multiple treatments is studied. PATIENTS AND METHODS: Botox 300 MU (mouse units) or Dysport 750 MU were injected into the detrusor wall in 365 sessions in 216 patients. The average age of the 144 men and 72 women was 32.3 years. Patients were investigated before treatment and at 6 weeks and 6 months after treatment. Maximal detrusor pressure, detrusor compliance, reflex volume and cystometric capacity were recorded. Use of anticholinergics and patient satisfaction were ascertained from questionnaires. Appropriate statistics were applied.
RESULTS: All urodynamic parameters improved. The use of anticholinergics decreased substantially. No differences were noted between the two preparations. The incontinence situation improved markedly. The effect of the treatment was noted after about 2 weeks and lasted for about 9 months.
CONCLUSIONS: Botulinum toxin A treatment in neurogenic detrusor overactivity patients is effective, long-lasting and repeatable. The treatment is minimally invasive and might be considered as an alternative to high-dosage anticholinergic medication. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996642     DOI: 10.1159/000251175

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  9 in total

1.  Botulinum toxin and urinary bladder disorders in women: new insight into an old problem.

Authors:  Ervin Kocjancic; Diaa E E Rizk
Journal:  Int Urogynecol J       Date:  2010-04-01       Impact factor: 2.894

2.  An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.

Authors:  Apostolos Apostolidis; Catherine Thompson; Xiaohong Yan; Sherif Mourad
Journal:  World J Urol       Date:  2012-11-18       Impact factor: 4.226

Review 3.  Medical Management of Neurogenic Bladder for Children and Adults: A Review.

Authors:  Elizabeth Lucas
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

4.  OnabotulinumtoxinA in the treatment of neurogenic bladder.

Authors:  Aziz Gulamhusein; Altaf Mangera
Journal:  Biologics       Date:  2012-08-28

5.  Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.

Authors:  Sheng-Fu Chen; Chia-Hwei Chang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2016-05-30       Impact factor: 4.546

6.  Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury.

Authors:  Giuseppe Lombardi; Stefania Musco; Giovanni Bacci; Maria Celso; Valerio Bellio; Giulio Del Popolo
Journal:  Int Braz J Urol       Date:  2017 Jul-Aug       Impact factor: 1.541

Review 7.  Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?

Authors:  Sheng-Fu Chen; Hann-Chorng Kuo
Journal:  Tzu Chi Med J       Date:  2020-07-29

8.  Trends in Procedures to Initiate Renal Replacement Therapy among People Living with Spina Bifida.

Authors:  Courtney S Streur; Nicholas M Moloci; Kate H Kraft; Aruna V Sarma; Vahakn B Shahinian; John M Hollingsworth
Journal:  J Urol       Date:  2020-07-27       Impact factor: 7.450

9.  The use of botulinum toxin for the treatment of overactive bladder syndrome.

Authors:  Bogdan Orasanu; Sangeeta T Mahajan
Journal:  Indian J Urol       Date:  2013-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.